92 related articles for article (PubMed ID: 20629525)
1. Addressing uncertainty regarding the utility of carbohydrate antigen-125 as a prognostic marker in non-Hodgkin lymphoma.
Ojha RP; Brown LM; Felini MJ; Singh KP; Thertulien R
Leuk Lymphoma; 2010 Sep; 51(9):1754-7. PubMed ID: 20629525
[No Abstract] [Full Text] [Related]
2. CA-125: a tumor marker in non-Hodgkin's lymphomas?
Pabst T; Ludwig C
J Clin Oncol; 1995 Jul; 13(7):1827-8. PubMed ID: 7602374
[No Abstract] [Full Text] [Related]
3. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
5. CA 125 elevations in patients with malignant lymphomas.
Fehm T; Beck E; Valerius T; Gramatzki M; Jäger W
Tumour Biol; 1998; 19(4):283-9. PubMed ID: 9679739
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in aggressive lymphoma: the contribution of novel biological markers.
Montserrat E
Ann Hematol; 2001; 80 Suppl 3():B42-4. PubMed ID: 11757705
[No Abstract] [Full Text] [Related]
9. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
[TBL] [Abstract][Full Text] [Related]
10. Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.
Namikawa T; Kawanishi Y; Fujisawa K; Munekage E; Iwabu J; Munekage M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2018 Apr; 48(4):388-394. PubMed ID: 29043453
[TBL] [Abstract][Full Text] [Related]
11. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Burney IA; Siddiqui T; Siddiqui I
Cancer; 1999 Feb; 85(3):755-6. PubMed ID: 10091750
[No Abstract] [Full Text] [Related]
12. The correlation between fetal hemoglobin and outcome in non-Hodgkin's lymphoma.
Wolk M; Newlands ES
Int J Biol Markers; 2004; 19(2):168-9. PubMed ID: 15255552
[No Abstract] [Full Text] [Related]
13. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
[TBL] [Abstract][Full Text] [Related]
14. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma.
Wu JZ; Tian T; Huang Y; Liang JH; Miao Y; Wang L; Xu J; Qu XY; Fan L; Li JY; Xu W
Cancer Biomark; 2016 Jul; 17(2):205-12. PubMed ID: 27434288
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.
Purdue MP; Lan Q; Kemp TJ; Hildesheim A; Weinstein SJ; Hofmann JN; Virtamo J; Albanes D; Pinto LA; Rothman N
Leukemia; 2015 Jun; 29(6):1429-31. PubMed ID: 25567136
[No Abstract] [Full Text] [Related]
16. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor necrosis factor-α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma.
El-Galaly TC; Bilgrau AE; Gaarsdal E; Klausen TW; Pedersen LM; Nielsen KR; Bæch J; Bøgsted M; Dybkær K; Johansen JS; Johnsen HE
Leuk Lymphoma; 2015; 56(8):2476-8. PubMed ID: 25563560
[No Abstract] [Full Text] [Related]
18. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma.
Yoh KA; Lee HS; Park LC; Lee EM; Shin SH; Park DJ; Ye BJ; Kim YS
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):43-9. PubMed ID: 24200518
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
